Lazard Capital makes a valuation call on Alkermes (ALKS -1.3%), downgrading the stock to Neutral from Buy after last week's run-up. Mizuho had a similar call on Thursday as sentiment seems to be that Phase III trial data is too far out to justify the enthusiasm surrounding top line results from Phase II clinicals.